Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

Amir Ansaripour; Carin A. Uyl-de Groot; W. Ken Redekop

首页> 外文期刊>PharmacoEconomics >Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

【24h】

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

机译：作者矫正：伊朗早期Her2阳性乳腺癌的佐剂曲据治疗：最佳治疗策略的成本效益和情景分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abstarct Page 95, Table?2, final row, second column: the mean Advanced treatment annual cost which

机译：摘要第95页，表？2，最终行，第二栏：平均先进治疗年度成本

著录项

来源
《PharmacoEconomics》 |2018年第4期|共1页
作者
Amir Ansaripour; Carin A. Uyl-de Groot; W. Ken Redekop;
展开▼
作者单位

Institute for Medical Technology Assessment Institute of Health Policy and Management Erasmus;

Institute for Medical Technology Assessment Institute of Health Policy and Management Erasmus;

Institute for Medical Technology Assessment Institute of Health Policy and Management Erasmus;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [J] . Amir Ansaripour, Carin A. Uyl-de Groot, W. Ken Redekop PharmacoEconomics . 2018,第4期

机译：作者矫正：伊朗早期Her2阳性乳腺癌的佐剂曲据治疗：最佳治疗策略的成本效益和情景分析
2. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [J] . Ansaripour Amir, Uyl-de Groot Carin A., Redekop W. Ken PharmacoEconomics . 2018,第1期

机译：伊朗早期海绵阳性乳腺癌的佐剂曲据疗法：最佳治疗策略的成本效益和情景分析
3. Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’ [J] . Amir Ansaripour, Carin A. Uyl-de Groot, W. Ken Redekop PharmacoEconomics . 2018,第3期

机译：回应“评论”伊朗早期海绵体乳腺癌的佐剂曲据治疗：最佳治疗战略的成本效益和情景分析“”
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Gut Microbiota and Trastuzumab Response in HER2-Positive Breast Cancer [D] . Di Modica, Martina. 2020

机译：肠道微生物群和胸瘤反应在Her2阳性乳腺癌中
6. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [O] . Amir Ansaripour, Carin A. Uyl-de Groot, W. Ken Redekop -1

机译：辅助曲妥珠单抗治疗伊朗早期HER2阳性乳腺癌：成本-效果和方案分析的最佳治疗策略。
7. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [O] . Ansaripour, Amir, Uyl-de Groot, Carin, Redekop, Ken 2017

机译：辅助曲妥珠单抗治疗伊朗早期HER2阳性乳腺癌：成本-效果和方案分析的最佳治疗策略。

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

摘要

著录项

相似文献

相关主题

期刊订阅